ADVMライブシグナル | Getagraph.comで利益を最大化

買う 108125 min ago

@ $2.19

発行日: 14 2月 2024 @ 23:34

リターン: 347.49%

前回のシグナル: 2月 13 - 06:00

前回のシグナル: 売る

リターン: 10.05 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:35):

Stats
本日の出来高	254 558
平均出来高	311 995
時価総額	203.40M
EPS	$0 ( 2024-04-04 )
次の収益日	( $-1.300 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.840
ATR14	$0.0460 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-03	Seyedkazemi Setareh	Buy	85 000	Stock Option (Right to Buy)
2023-10-03	Soparkar Peter	Buy	130 000	Stock Option (Right to Buy)
2023-10-03	Fischer Laurent	Buy	315 000	Stock Option (Right to Buy)
2024-02-12	Seyedkazemi Setareh	Buy	400 000	Stock Option (Right to Buy)
2024-02-12	Fischer Laurent	Buy	1 104 200	Stock Option (Right to Buy)

INSIDER POWER
97.11
Last 100 transactions
Buy: 14 665 896 \| Sell: 1 551 540

ボリューム相関

長: -0.13 (neutral)

短: -0.03 (neutral)

Signal:(61.509) Neutral

Adverum Biotechnologies 相関

10 最も正の相関
RVNC	0.965
VCNX	0.964
LYT	0.963
SBET	0.959
RSLS	0.957
HA	0.957
BCLI	0.956
FDMT	0.955
STKS	0.954
TNYA	0.953

10 最も負の相関
RMRM	-0.971
ACQR	-0.963
TBSA	-0.962
HERA	-0.962
NVSA	-0.961
FRSG	-0.961
LEGA	-0.96
FTPA	-0.96
GXII	-0.96
AGGR	-0.96

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Adverum Biotechnologies 相関 - 通貨/商品

0.79
( moderate )

0.76
( moderate )

0.00
( neutral )

0.71
( moderate )

0.73
( moderate )

-0.85
( strong negative )

Adverum Biotechnologies 財務諸表

Annual	2023
収益:	$3.60M
総利益:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2023
収益:	$3.60M
総利益:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2022
収益:	$0
総利益:	$-6.53M (0.00 %)
EPS:	$-15.57

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.709

Financial Reports:

No articles found.

Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.